JACKSONVILLE, Fla., Sept. 8 /PRNewswire/ -- Sinapis Pharma, Inc is pleased to announce the addition of Frederick Frank as a consultant to the company. Mr. Frank will leverage his decades of experience to advise the company on merger and acquisition opportunities and fund raising for clinical trial development. Sinapis Pharma has discovered and is patenting a new therapeutic approach to treating stroke in humans using Methamphetamine in an intravenous (IV) formulation.
Mr. Frank will advise Sinapis on its M & A corporate development efforts to find a merger partner for Sinapis as the company conducts its Proof of Concept clinical trial. Sinapis is in discussions with potential pharma partners to form a collaboration that will provide Sinapis funding for its Phase I and IIA clinical trials, while granting the right to acquire Sinapis if the two trials are successful. Sinapis management estimates that the Phase IIA Proof of Concept clinical trial will be complete within approximately twenty-eight (28) months.
Mr. Frank is former Vice Chairman of Lehman Brothers where he spent thirty years building the premier big pharma and healthcare investment banking practice in the U.S. and Europe. Mr. Frank is the leading investment banker internationally for pharmaceutical company mergers, acquisitions and equity fund raising.
Sinapis Pharma, Inc (www.sinapispharma.com) is an early stage drug development company whose lead compound methamphetamine, as an intravenous infusion for the treatment of acute stroke and brain injury, has shown robust pre-clinical efficacy. It is a powerful neuroprotective agent with a remarkable 12 hour therapeutic window in animal studies of stroke. Sinapis CEO Donald Picker, Ph.D. states: "We are thrilled to have Fred Frank join our team at Sinapis. His creativity and depth of relationships in the pharmaceutical industry will be invaluable as we execute our development plan."
|SOURCE Sinapis Pharma, Inc|
Copyright©2009 PR Newswire.
All rights reserved